We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

18 hedge funds and large institutions have $430K invested in Titan Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 12 → 18 (+6)

0.02% more ownership

Funds ownership: 0.2% → 0.21% (+0.02%)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

40% less capital invested

Capital invested by funds: $722K → $430K (-$292K)

Holders
18
Holders Change
+6
Holders Change %
+50%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
5
Closed
–
Calls
$83K
Puts
–
Net Calls
+$83K
Net Calls Change
+$61K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$58.7K
2
Group One Trading
Group One Trading
Illinois
+$44.8K
3
Millennium Management
Millennium Management
New York
+$30.4K
4
VF
Virtu Financial
New York
+$23.2K
5
WPA
Winning Points Advisors
Florida
+$17.6K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$136K
2
UBS Group
UBS Group
Switzerland
-$4.97K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.57K
4
TC
Trust Company
Kansas
-$1K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$422
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$210K -$422 -14 -0.1%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$54K -$60 -2 -0.1%
Group One Trading
3
Group One Trading
Illinois
$46K +$44.8K +1,488 +198%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$40K +$58.7K +1,947 New
Millennium Management
5
Millennium Management
New York
$21K +$30.4K +1,009 New
Renaissance Technologies
6
Renaissance Technologies
New York
$20K +$9.82K +326 +50%
VF
7
Virtu Financial
New York
$16K +$23.2K +771 New
WPA
8
Winning Points Advisors
Florida
$15K +$17.6K +584 New
UBS Group
9
UBS Group
Switzerland
$4K -$4.97K -165 -46%
Simplex Trading
10
Simplex Trading
Illinois
$3K +$5.73K +190 New
LFA
11
Level Financial Advisors
New York
$1K +$1.48K +49 New
APA
12
American Portfolios Advisors
New York
$23 – – –
Morgan Stanley
13
Morgan Stanley
New York
– -$136K -4,523 -100%
TRCT
14
Tower Research Capital (TRC)
New York
– -$1.57K -52 -91%
TC
15
Trust Company
Kansas
– -$1K – –
Bank of America
16
Bank of America
North Carolina
– +$30 +1 +10%

TTNP Hedge Fund Activity: Q4 2021 in Review

18 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2021, worth a combined $430K — down 40% from $722K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TTNP positions and 0 closed out — a net gain of 6 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $58.7K. The largest seller was Morgan Stanley, cutting an estimated $136K.

  • 18 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2021, up from 12 in Q3 2021.
  • Funds reported $430K of Titan Pharmaceuticals stock for Q4 2021, down 40% quarter-over-quarter.
  • 6 funds opened new Titan Pharmaceuticals positions in Q4 2021 and 0 closed out, a net change of +6 holders.
  • The largest Titan Pharmaceuticals buyer in Q4 2021 was Susquehanna International Group, an estimated $58.7K added.
  • The largest Titan Pharmaceuticals seller in Q4 2021 was Morgan Stanley, an estimated $136K sold.

Based on aggregated 13F filings for Q4 2021.